Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Losmapimod in Adult Subjects With COVID-19 (LOSVID STUDY)

NCT04511819 is registered in ClinicalTrials.gov with Fulcrum Therapeutics as lead sponsor.

NCT NCT04511819
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04511819 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Losmapimod in Adult Subjects With COVID-19 (LOSVID STUDY)
Lead sponsor
Fulcrum Therapeutics
Phase
Phase 3
Overall status
Terminated
Start date
August 28, 2020
Completion date
March 31, 2021
Enrollment
52 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19